Closed · W81XWH-17-ALSRP-TDA · CFDA 12.420 · Discretionary
DoD ALSRP Therapeutic Development Award
Federal grant opportunity posted by Defense Health Agency Contracting Activity - DHACA, cataloged on Grants.gov.
- Varies
- Award range
- Closed
- Status
- August 31, 2017
- Close date
- 2
- Expected awards
The verdict
DoD ALSRP Therapeutic Development Award is a closed discretionary listing from Defense Health Agency Contracting Activity - DHACA that offered Varies by applicant across 2 expected awards. Future funding cycles may be published under the same CFDA number. PlainGrants indexes 1,795 other opportunities from Defense Health Agency Contracting Activity - DHACA.
- Varies
- award range
- Closed
- application status
- 2
- expected awards
- 12.420
- CFDA program
Archived opportunity record
DoD ALSRP Therapeutic Development Award is closed (last close August 31, 2017). Check the agency catalog for replacement NOFOs. Defense Health Agency Contracting Activity - DHACA still indexes 1,795 other opportunities here.
According to Grants.gov (extract vintage 2026-08-10), this record reflects the officially published listing. See methodology.
Deadline tracker
Application window closed
Closed August 31, 2017
Est. Total Funding
$3,200,000
Expected Awards
2
Instrument
Grant
Description
The Therapeutic Development Award supports a wide range of development activities ranging from validation of therapeutic leads to U.S. Food and Drug Administration (FDA) Investigational New Drug (IND) application submission. The proposed studies are expected to be empirical in nature and product-driven. Applications supported by this award must begin with lead compounds in hand. Examples of activities that will be supported by this award include: • Secondary validation of lead compounds obtained from screening or by other means to demonstrate target selectivity and mechanism of action, • Optimization of potency and pharmacological properties, development of structure- activity maps via synthesis, and testing of derivatives and sister compounds, • Studies on formulation and stability, • Development of Good Manufacturing Practice (GMP) production methods, and • Collection of data for FDA IND applications, to include compound characterization, absorption, distribution, metabolism, and excretion (ADME) studies, and dose/response and toxicology studies. In parallel with lead compound validation and development, applicants are strongly encouraged to assess in vivo efficacy or target engagement (measurement of target binding or proximal downstream effects) in a relevant preclinical ALS model(s). Applications must include preliminary data and other supporting information relevant to the phase(s) of the preclinical development, such as the following: • Background data supporting the putative mechanism of action as a viable therapeutic approach • An identified bioactive compound or limited group of identified lead molecules with: • Proof of identity and purity • Selectivity for the intended target over closely related targets (when the target is known) • Availability of primary and secondary in vitro bioactivity assays for optimization or structure-activity relationship studies • Availability of appropriate preclinical animal models of ALS to assess in vivo efficacy or desirable mechanism-specific drug activity at the intended target (target engagement) Investigators interested in basic research focused on ALS drug discovery are encouraged to apply for the FY17 ALSRP Therapeutic Idea Award (Funding Opportunity Number: W81XWH- 17-ALSRP-TIA), which does not require preliminary data (http://cdmrp.army.mil/funding/alsrp).
Catch-all / unrestricted eligibility mark · W81XWH-17-ALSRP-TDA
Grants.gov marks DoD ALSRP Therapeutic Development Award with a catch-all / unrestricted eligibility code (Unrestricted / see official listing). Read the official announcement text for the real applicant filter — the code alone is not a door list. The extract does not mark applicant cost-sharing as required. Instrument: Grant. Funding-activity code maps to Science and Technology / R&D (ST). This eligibility-code string dominates the Defense Health Agency Contracting Activity - DHACA book (1,791 peers, 100% of 1,796).
- Code 99
- Unrestricted / see official listing
Codes are Grants.gov eligibility category values from the extract vintage 2026-08-10. Confirm the full eligibility statement on the official listing or the Grants.gov eligibility reference.
Official Listing on Grants.gov
View full details, application forms, and submission instructions.
Agency Contact
CDMRP Help Desk Phone: 301-682-5507 Email: help@eBRAP.org
More from Defense Health Agency Contracting Activity - DHACA
DoW Neurofibromatosis Synergistic Idea Award
DoW Neurofibromatosis Investigator-Initiated Research Award
DoW Neurofibromatosis Research Academy – Scholar Award
DoW Neurofibromatosis Exploration-Hypothesis Development Award
DOW Combat Readiness – Medical Research Program Translational Research Award
What to do next
DoD ALSRP Therapeutic Development Award is closed; use the parent program and agency catalog for the next funding cycle.
- Browse open federal opportunities in the same category when this listing is closed. Open opportunities
- Look up CFDA 12.420 across all indexed listings before you commit to this opportunity alone. Eligibility finder
- Compare award ranges across federal categories before you pick a single CFDA. All categories
Opportunity deadlines and eligibility change on Grants.gov; PlainGrants mirrors the extract and is not the submission system.
Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.
Read our methodology - how this data is sourced, computed, and verified.
| Publisher | PlainGrants |
| Sources | the SAM.gov Assistance Listings and Grants.gov |